Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL)
Titel:
Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL)
Auteur:
Strati, Paolo Keating, Michael J. O'Brien, Susan M. Burger, Jan Ferrajoli, Alessandra Jain, Nitin Estrov, Zeev Jorgensen, Jeffrey Faderl, Stefan H. Wierda, William G.